When does emicizumab’s patent expire?
Patent expiry dates for emicizumab (Hemlibra) depend on the specific country and the particular patent (or patent family) covering the drug, its formulation, and related methods. The information provided here does not include emicizumab’s patent list or jurisdiction-specific expiry terms, so an exact date can’t be stated reliably without those sources.
Which patents usually control emicizumab’s exclusivity (and why dates vary)?
For biologics like emicizumab, the market “lock” is often driven by multiple layers of IP, which can extend protection beyond the first filing, including:
- Patent families on the antibody and its engineering.
- Secondary patents on specific dosing regimens, manufacturing processes, or formulations.
- Jurisdiction-specific patent terms, including adjustments and extensions permitted by local law.
Because each component can expire on different schedules and in different jurisdictions, “the” expiry date is not a single number globally.
Does emicizumab have pediatric exclusivity or regulatory exclusivity that extends the timeline?
Even after patent protection ends, additional regulatory exclusivities can affect launch timing for competitors in some countries. Whether this applies to emicizumab depends on the approval jurisdiction and the relevant exclusivity regime (for example, supplemental protection mechanisms in the US/EU/UK). The necessary jurisdictional details and regulatory documents are not included here, so no definitive timeline can be provided.
Can biosimilars or competing products enter before every patent expires?
Yes, sometimes. Competitors may enter if they are able to avoid infringement of the still-active patents (or if patents are successfully challenged), even while other patents within the same portfolio remain in force. Entry timing can therefore differ by:
- Which claims are considered infringed,
- Whether a launch triggers litigation,
- Settlement outcomes, and
- Court decisions affecting enforceable claims.
Where can you check the exact expiry date you care about?
To get a precise emicizumab patent expiry date, you need:
- The country (US, EP/EU member state, UK, Japan, etc.).
- The specific patent family or patent numbers being asserted.
- The regulatory exclusivity/marketing authorization exclusivity rules for that jurisdiction.
Common places to verify include national patent registers and structured patent databases (and, for regulatory exclusivity, the relevant medicines regulator’s exclusivity documentation). With the country and (ideally) the patent numbers, the expiry date can be pinned down accurately.
What to tell me so I can give a concrete expiry date
Share any of the following and I can narrow to a specific expiry timeline:
- Country/jurisdiction (e.g., US only, or EU/UK only)
- Whether you want the expiry of the “first” core patent vs. all blocking patents
- Patent numbers or a link/list you’re working from
- Whether you mean patent expiry or regulatory exclusivity expiry
Sources
No sources were provided in the prompt, so none are cited.